Erectile function after stereotactic body radiotherapy for localized prostate cancer

Area of Science:

• Oncology
• Radiation Oncology
• Urology

Background:

• Prostate stereotactic body radiotherapy (SBRT) is an effective treatment for localized prostate cancer.
• Understanding long-term functional erection rates after SBRT is crucial for patient quality of life.
• Predictive factors for post-treatment erectile function require further elucidation.

Purpose of the Study:

• To determine the functional erection rate following prostate SBRT.
• To develop a prognostic model for predicting erectile function outcomes.
• To compare SBRT erectile function rates with other radiation modalities.

Main Methods:

• Prospective study of 373 men with localized prostate cancer treated with SBRT.
• Health-related quality of life (HRQoL) assessed using EPIC-26, defining functional erections as 'firm enough for intercourse'.
• Logistic regression models used to predict 24- and 60-month erection rates; comparisons made with external beam radiation therapy (EBRT) and brachytherapy.

Main Results:

• At 24 months, 57% of men with baseline erections retained function; 45% retained function at 60 months.
• Higher baseline sexual HRQoL and younger age were associated with better 24-month erectile function.
• Body mass index became a significant factor at 60 months; prognostic models demonstrated excellent discrimination (c-index 0.81-0.84).

Conclusions:

• Intermediate- to long-term erectile function after SBRT is promising.
• Erection rates post-SBRT are not significantly different from EBRT or brachytherapy.
• A developed prognostic model can assist clinicians in counseling patients on expected erectile function post-SBRT.